BioRestorative Therapies announces partnership with David Goldberg, M.D.

BioRestorative Therapies (BRTX) announced a strategic partnership with David Goldberg, M.D., J.D. Through the agreement, the Company is seeking to accelerate both scientific validation and market adoption of its regenerative BioCosmeceutical platform across the Company’s expanding commercial ecosystem. As part of this collaboration, the Company intends for Dr. Goldberg to lead a prospective, controlled human clinical study designed to generate comparative outcome data evaluating improvements in skin appearance, texture, and overall quality relative to current aesthetic treatment benchmarks. The study is intended to be conducted using BioRestorative’s secretome-derived biologics – enriched with exosomes, growth factors, cytokines, and peptides – manufactured in the Company’s cGMP, ISO-7-certified cleanroom facility. Results are expected to support publication-quality evidence that further defines the platform’s clinical role across professional and consumer applications.